Cyfuse Biomedical K.K. Cash Flow Statement

Financials in millions JPY. Fiscal year is January - December.

Millions JPY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-761	-869	-586	-471	-
Depreciation & Amortization	37	38	40	63	-
Other Operating Activities	80	43	124	5	-
Change in Accounts Receivable	15	-3	-3	44	-
Change in Inventory	-33	-9	-5	21	-
Change in Accounts Payable	49	22	-20	-3	-
Change in Other Net Operating Assets	79	18	-112	-62	-
Operating Cash Flow	-534	-760	-562	-403	-
Capital Expenditures	-47	-8	-19	-228	-
Investment in Securities	-350	-	-	-200	-
Other Investing Activities	-	-	-	-2	-
Investing Cash Flow	-397	-8	-19	-430	-
Short-Term Debt Issued	-	-	73	328	-
Long-Term Debt Issued	489	-	-	90	-
Total Debt Issued	489	-	73	418	-
Short-Term Debt Repaid	-32	-51	-	-	-
Long-Term Debt Repaid	-18	-18	-77	-82	-
Total Debt Repaid	-50	-69	-77	-82	-
Net Debt Issued (Repaid)	439	-69	-4	336	-
Issuance of Common Stock	817	17	22	2,329	-
Other Financing Activities	-	-	-	-7	-
Financing Cash Flow	1,256	-52	18	2,658	-
Miscellaneous Cash Flow Adjustments	-2	-1	-	-1	-
Net Cash Flow	323	-821	-563	1,824	-
Free Cash Flow	-581	-768	-581	-631	-
Free Cash Flow Margin	-252.61%	-1422.22%	-952.46%	-168.72%	-
Free Cash Flow Per Share	-66.01	-95.40	-74.37	-236.54	-
Cash Interest Paid	14	9	9	7	-
Cash Income Tax Paid	2	2	2	2	-
Levered Free Cash Flow	-483.5	-585.25	-446.88	-458	-
Unlevered Free Cash Flow	-474.13	-579	-440.63	-453.63	-
Change in Working Capital	110	28	-140	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.